Accuracy and reproducibility of conformal radiotherapy using data from a randomised controlled trial of conformal radiotherapy in prostate cancer (MRC RT01, ISRCTN47772397)

S Stanley, S Griffiths, M R Sydes, A R Moore, I Syndikus, D P Dearnaley, RT01 Radiographer Trial Implementation Group, S Stanley, S Griffiths, M R Sydes, A R Moore, I Syndikus, D P Dearnaley, RT01 Radiographer Trial Implementation Group

Abstract

Aims: The MRC RT01 trial used conformal radiotherapy to the prostate, a method that reduces the volume of normal tissue treated by 40-50%. Because of the risk of geographical miss, the trial used portal imaging to examine whether treatment delivery was within the required accuracy.

Material and methods: In total, 843 patients were randomly assigned to receive 64 Gy in 32 fractions over 6.5 weeks or 74 Gy in 37 fractions over 7.5 weeks. Field displacements and corrections were recorded for all imaged fractions. Displacement trends and their association with time, disease and treatment set-up characteristics were examined using univariate and multivariate analyses. A Radiographer Trial Implementation Group (RTIG) was set up to inform the quality assurance process and to promote the development of best practice.

Results: Treatment isocentre positioning was within 5 mm in every direction on 6238 (83%) of the 7535 fractions imaged. In total, 532 (81%) of 695 included patients had at least one > or = 3 mm displacement and 415 (63%) had at least one > or = 5 mm displacement. Univariate, multivariate and stepwise models of > or =5 mm displacements showed an increased likelihood of displacement in weeks 1 and 2 with low melting point alloy (LMPA) blocks compared with multileaf collimators, film verification compared with electronic portal imaging (EPI) and increased number of fractions imaged. Except for LMPA, this was also seen for > or = 5 mm displacements in weeks 3-6.

Conclusions: Accurate conformal treatment was delivered. The use of EPI was associated with increased reported accuracy. The RTIG was a crucial part of the quality assurance process.

Figures

Fig. 1
Fig. 1
Size and direction of reported corrections and displacements in imaged fractions.
Fig. 2
Fig. 2
Four-way panel graphs of displacements by week.

References

    1. National Institute for Health and Clinical Excellence . National Institute for Health and Clinical Excellence; London: 2002. NHS NICE Guidance on Cancer Services: Improving Outcomes in Urological Cancers – the Manual, 2002.
    1. Sydes M.R., Stephens R.J., Moore A.R. Implementing the UK Medical Research Council (MRC) RT01 trial (ISRCTN 47772397): methods and practicalities of a randomised controlled trial of conformal radiotherapy in men with localised prostate cancer. Radiother Oncol. 2004;72:199–211.
    1. Dearnaley D.P., Sydes M.R., Langley R.E. The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial (ISRCTN47772397) Radiother Oncol. 2007;83(3):31–41.
    1. Dearnaley D.P., Sydes M.R., Graham J.D. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2007;8(6):475–487.
    1. Dearnaley D.P. Radiotherapy of prostate cancer: established results and new developments. Semin Surg Oncol. 1995;11:50–59.
    1. Mayles W.P.M., Moore A.R., Aird E.G.A. Questionnaire based quality assurance for the RT01 trial of dose escalation in conformal radiotherapy for prostate cancer (ISRCTN 47772397) Radiother Oncol. 2004;73:199–207.
    1. Moore A.R., Stanley S., Bidmead A.M. Quality assurance of dosimetry in UK MRC RT01 trial of dose escalation using conformal radiotherapy in prostate cancer (ISRCTN 47772397) Clin Oncol. 2003;15(2):S8–S9.
    1. Griffiths S., Stanley S., Sydes M., RT01 Radiographers Group on behalf of all the RT01 Collaborators Recommendations on best practice for radiographer set up of conformal radiotherapy treatment for patients with prostate cancer: experience developed during the MRC RT01 trial (ISRTCN 47772397) J Radiother Pract. 2005;4:107–117.
    1. Hurkmans C.W., Remeijer P., Lebesque J.V. Set-up verification using portal imaging: review of current clinical practice. Radiother Oncol. 2001;58:105–120.
    1. Mubata C.D., Bidmead A.M., Ellingham L.M. Portal imaging protocol for radical dose-escalated radiotherapy treatment of prostate cancer. Int J Radiat Oncol Biol Phys. 1998;40:221–231.
    1. De Neve W., Van den Heuvel F., Coghe M. Interactive use of portal imaging in pelvic irradiation. Int J Radiat Oncol Biol Phys. 1993;25:517–524.
    1. Greer P.B., Mortesen T.M., Rad D.T. Comparison of two methods for anterior posterior isocenter localization in pelvic radiotherapy using electronic portal imaging. Int J Radiat Oncol Biol Phys. 1998;41:1193–1199.
    1. Bel A., Vos P.H., Rodrigus P.T. High-precision prostate cancer irradiation by clinical application of an off-line patient setup verification procedure, using portal imaging. Int J Radiat Oncol Biol Phys. 1996;35:321–332.
    1. Dearnaley D.P., Hall E., Lawrence D. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. Br J Cancer. 2005;92:488–498.
    1. Crook J.M., Raymond Y., Salhani D. Prostate motion during standard radiotherapy as assessed by fiducial markers. Radiother Oncol. 1995;37:35–42.
    1. De Boer H.C.J., Heijmen B.J.M. A protocol for the reduction of systematic patient setup errors with minimal portal imaging workload. Int J Radiat Oncol Biol Phys. 2001;50:1350–1365.
    1. Denham J.W., Dally M.J., Hunter K. Effective decision making following a portal film: the results of a pilot study. Int J Radiat Oncol Biol Phys. 1993;26:869–876.
    1. Perera T., Moseley J., Munro P. Subjectivity in interpretation of portal films. Int J Radiat Oncol Biol Phys. 1999;45(2):529–534.
    1. Baumert B.G., Zagralioglu O., Davis J.B. The use of a leg holder immobilisation device in 3D-conformal radiation therapy of prostate cancer. Radiother Oncol. 2002;65:47–52.
    1. Bentel G.C., Marks L.B., Sherouse G.W. The effectiveness of immobilisation during prostate irradiation. Int J Radiat Oncol Biol Phys. 1995;31(1):143–148.
    1. Bieri S., Mirabell R., Nouet P. Reproducibility of conformal radiation therapy in localised carcinoma of the prostate without rigid immobilisation. Radiother Oncol. 1996;38:223–230.
    1. Dawson L., Mah K., Franssen E. Target position variability throughout prostate radiotherapy. Int J Radiat Oncol Biol Phys. 1998;42(5):1155–1161.
    1. El-Gayed A.A., Bel A., Vijlbrief R. Time trend of patient setup deviations during pelvic irradiation using electronic portal imaging. Radiother Oncol. 1993;26:162–171.
    1. Hanley J., Lumley M.A., Mageras G.S. Measurement of patient positioning errors in three-dimensional conformal radiotherapy of the prostate. Int J Radiat Oncol Biol Phys. 1997;37(2):435–444.
    1. Rosenthal S.A., Roach M., Goldsmith B.J. Immobilisation improves the reproducibility of patient positioning during 6-field conformal radiation therapy for prostate carcinoma. Int J Radiat Oncol Biol Phys. 1993;27:921–926.
    1. Soffen E.M., Hanks G.E., Hwang C.C., Chu J.C.H. Conformal static field therapy for low volume low grade prostate cancer with rigid immobilisation. Int J Radiat Oncol Biol Phys. 1991;20:141–146.
    1. Song P.Y., Washington M., Vaida F. A comparison of four patient immobilisation devices in the treatment of prostate cancer patients with three dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys. 1996;34(1):213–219.
    1. Suter B., Shoulders B., MacClean M. Machine verification radiographs: an opportunity for role extension. Radiography. 2000;6:245–251.
    1. Academic Clinical Oncology and Radiobiology Research Network (ACORRN)
    1. Rudat V., Scraube P., Oetzel Combined error of patient positioning variability and prostate motion uncertainty in 3D conformal radiotherapy of localised prostate cancer. Int J Radiat Oncol Biol Phys. 1996;35(5):1027–1034.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit